As AstraZeneca’s Head of US Corporate Affairs for Respiratory & Immunology (R&I), Vaccines & Immune Therapies (V&I) Blake McEvoy is responsible for driving the development and execution of integrated external and internal Corporate Affairs strategies, working closely with senior leadership of the US and Global therapy area teams and departments within US Corporate Affairs spanning External Affairs, Internal Communications, Advocacy and Alliance, Policy and Government Affairs to deliver fully integrated communications plans that help achieve the therapy area’s vision, goals and objectives.
Known for his collaborative and humble yet go-getter spirit, Blake has been with AstraZeneca for over a decade, working across each US therapy area and Mature Brands portfolio with increasing responsibility in US and Global Corporate Affairs. He joined the Global Corporate Affairs team more than three years ago to lead communications for the metabolism portfolio within the Cardiovascular, Renal and Metabolism therapy area (CVMR), overseeing the Corporate Affairs strategy for the CVD-REAL study and DELCARE-TIMI 58 trial results, and industry-leading DapaCare clinical development program for Farxiga.
Most recently, Blake served as the Global Patient Centricity, Strategy and Engagement Leader for Global Corporate Affairs under Rich Buckley, Chief Corporate Affairs Officer, where he created AstraZeneca’s first and now annual “Patient Week,” alongside internal communities and resources to facilitate a patient-centric culture. While in this role, Blake oversaw the launch of the company’s first Global patient-centricity strategy, scorecard and benchmark in partnership with teams across AstraZeneca and external partners.
Before kickstarting his career in the world of pharmaceutical communications, Blake also worked in the agency setting (Boscobel Marketing Communications, Inc.). He attended Pennsylvania State University, graduating with honors, where he received a bachelor’s degree in journalism and philosophy.
